Chen Fang, PharmD, RPh

A case study presented at the 2022 CMSC Annual Meeting reviews a 47-year-old male patient who experienced relapsing steroid-responsive encephalomyelitis after SARS-CoV-2 infection and subsequent COVID-19 infection.

Presenting at CMSC 2022, researchers assessed the risk for reproductive and embryofetal toxicity in women exposed to ponesimod during pregnancy.

Researchers reported results from an interim analysis of an ongoing open-label extension to study the safety and efficacy of adults with anti-acetylcholine receptor antibody-positive generalized myasthenia gravis.

New data about Pfizer COVID-19 efficacy after the first dose suggests high efficacy, raising questions about potential alternative dosing schedules.

We speak with Mildred Solomon, EdD, President of the Hastings Center and Professor of Global Health and Social Medicine at Harvard Medical School, where she directs the school’s Fellowship in Bioethics, about the COVID-19 pandemic, health equity, and vaccine distribution.

Johnson & Johnson released interim analysis of its phase 3 EMSEMBLE trial for Ad.26.COV2, and provided more insight on overall protection in various countries, variant protection, and clinical outcomes.

Anthony Fauci, MD, discusses public trust in science, vaccine progress, and vaccine facilitation as the United States heads toward a new phase of the pandemic.

George Abraham, MD, offers insight into where the United States currently stands with regard to the COVID-19 pandemic, vaccine development, barriers to care in various patient populations, and the evolving roles of infectious disease specialists.